KOSDAQBiotech & Pharma067630

HLB Life Science

₩2,285▼ 2.77%2026-11-18 close
Market Cap
₩278.6B
Turnover
₩200M
Volume
100K
Shares out.
120M
PER
—
PBR
1.2×
EPS
-₩187
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Loss Narrowing Amid Business Restructuring

HLB Life Science is restructuring its portfolio around profitability, including halting its OEM business, but revenue fell sharply in 2025 and the company has recorded losses for five consecutive quarters, so whether earnings turn positive is the key point to monitor.

  1. 1

    Revenue in 2025 was KRW 45.8 billion, down 55.3% from the prior year, and the operating loss was KRW 22 billion.

  2. 2

    The 2025 net loss attributable to controlling shareholders was KRW 99.8 billion, far larger than the operating loss, suggesting a large impact from non-operating items.

  3. 3

    The OEM division has been suspended since June 30, 2026, and press reports put its 2025 revenue at 24.4% of consolidated revenue.

  4. 4

    The operating loss in the third quarter of 2026 narrowed to KRW 3.49 billion from a year earlier, but the net loss attributable to controlling shareholders widened to KRW 26.4 billion from the prior quarter.

  5. 5

    Following a KRW 15.7 billion exchangeable bond issuance in January 2026, short-term borrowings doubled from the end of 2025 to the end of the first half of 2026.

02

Business structure

HLB Life Science is a bio and pharmaceutical company within the HLB Group, generating revenue mainly from medical devices, Medicare (in vitro diagnostics) and OEM manufacturing.

In July 2022 it merged the in vitro diagnostics firm Aim and reorganized it as the Medicare division, which press reports say has accounted for a large share of revenue since the merger.

On May 15, 2026, the board approved ending the OEM division within the Medicare division, which handles in vitro diagnostic kits and other plastic injection products. The company said it would exit low-profit businesses as demand in diagnostics fell after the endemic shift and competition intensified.

The OEM division has been suspended since June 30, 2026, and press reports put its 2025 revenue at KRW 11.16 billion, equal to 24.4% of consolidated revenue that year.

Management says exports of medical devices are growing, and according to the company's IR material, the standalone export ratio rose from 4.6% in 2024 to 16.0% in 2025.

A Company Monitor summary shows medical devices and Medicare as the largest revenue segments, with construction and engineering also holding a meaningful share.

Drug development is handled by the subsidiary HLB Life Science R&D, established in April 2022, and the R&D-to-revenue ratio has risen since 2022 according to the same data.

Compared with drug-pipeline-focused peers in the bio and pharmaceutical sector, the company has a manufacturing-centered structure with a large share of medical device and diagnostic product sales.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩13.6B-₩3.8B−28.2%
2025Q4₩10.9B-₩5.8B−53.0%
2026Q1₩15.2B-₩6.5B−42.5%
2026Q2₩14.7B-₩7.6B−51.6%
2026Q3₩15.2B-₩3.5B−23.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩99.6B-₩20.2B-₩54.3B−20.2%−23.1%74.4%
2023₩98B-₩24.5B-₩6B−25.0%−2.6%83.2%
2024₩102.2B-₩24.8B₩6.1B−24.3%1.5%35.2%
2025₩45.8B-₩22B-₩99.8B−48.1%−33.6%60.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

Annual revenue was KRW 99.6 billion in 2022, KRW 98 billion in 2023 (down 1.6% year over year), and KRW 102.2 billion in 2024 (up 4.3%), making 2024 the largest year of 2022 to 2025. Revenue in 2025 was KRW 45.8 billion, down 55.3% year over year, making it the smallest year in the period.

The filing attributes the 2025 revenue decline to fair value changes from asset valuation and changes in the consolidation scope following an equity disposal.

Operating losses were KRW 20.2 billion in 2022, KRW 24.5 billion in 2023 (losses continued and widened), KRW 24.8 billion in 2024 (losses continued and widened), and KRW 22 billion in 2025 (losses continued and narrowed), so the company has recorded losses for four consecutive years from 2022 to 2025.

The operating margin was -20.2% in 2022, -25.0% in 2023 and -24.3% in 2024, and worsened to -48.1% in 2025. The 2025 operating loss shrank in won terms, but because revenue fell sharply, the loss ratio widened.

Net income attributable to controlling shareholders was a loss of KRW 54.3 billion in 2022 and a loss of KRW 5.98 billion in 2023, then turned to a profit of KRW 6.14 billion in 2024 before swinging back to a loss of KRW 99.8 billion in 2025.

The 2024 profit came despite continued operating losses, which suggests non-operating items played a large role. The 2025 controlling-shareholder net loss of KRW 99.8 billion, far larger than the KRW 22 billion operating loss, also points to heavy non-operating losses.

The debt-to-equity ratio rose to 60.6% at the end of 2025 from 35.2% in 2024. Operating cash flow was negative in all four years: KRW -29.7 billion in 2022, KRW -10 billion in 2023, KRW -32 billion in 2024 and KRW -22.9 billion in 2025.

On a quarterly basis, revenue was KRW 13.6 billion in the third quarter of 2025, KRW 10.9 billion in the fourth quarter (down 19.5% from the prior quarter), KRW 15.2 billion in the first quarter of 2026 (up 38.8%), KRW 14.7 billion in the second quarter (down 3.6%), and KRW 15.2 billion in the third quarter (up 3.6% from the prior quarter and up 11.7% year over year).

Operating losses widened from KRW 3.84 billion in the third quarter of 2025 to KRW 5.8 billion, KRW 6.45 billion and KRW 7.56 billion in the following three quarters, then narrowed to KRW 3.49 billion in the third quarter of 2026, and the company has recorded losses for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026.

Net income attributable to controlling shareholders turned to a profit of KRW 20.1 billion in the fourth quarter of 2025, then showed losses of KRW 7.8 billion, KRW 8.7 billion and KRW 26.4 billion in the first three quarters of 2026, which is three consecutive quarters of losses.

The combined net loss attributable to controlling shareholders over the last four quarters was KRW 22.8 billion. The fourth-quarter profit and the large third-quarter 2026 loss do not match the size of the operating losses, which shows that swings in non-operating items drove quarterly net results.

Press reports said first-half 2026 revenue rose 40.8% year over year to KRW 29.9 billion, while the operating loss widened 13.2% to KRW 14 billion.

05

Industry analysis

The diagnostics market has moved from the pandemic-driven surge to an endemic phase in which demand is shrinking and competition is intensifying. The company said it exited diagnostic kits and plastic injection OEM work, which had lower added value, in response to these changes.

As a result, the revenue mix is shifting toward medical devices and self-developed products, and according to the company's IR material, the standalone export ratio rose from 4.6% in 2024 to 16.0% in 2025. A growing overseas share partly offsets weaker domestic diagnostics demand.

Whether higher exports have translated into better profitability is not yet clear from the reported operating results.

Compared with listed bio and pharmaceutical companies that are growing around drug pipelines and contract manufacturing, HLB Life Science has a larger share of manufacturing and medical device sales, so sector conditions feed directly into revenue.

Pipeline-focused companies show earnings swings tied to clinical and approval timelines, while this company is more exposed to product volumes and price competition. Its position sits between the stability of manufacturing-based revenue and the uncertainty of drug development results.

Because the company has many asset and funding flows with other HLB Group affiliates, the effect of the restructuring also depends on intra-group transactions.

06

Outlook

Since the March 2026 annual shareholders' meeting, under CEO Baek Yun-gi, the company has pursued a restructuring of its portfolio around profitability. It said short-term revenue swings are unavoidable as it removes low-profit businesses.

It also plans to strengthen profitability and financial stability over the medium to long term through export growth in medical devices and a focus on high-value products. On January 22, 2026, the board approved a private exchangeable bond of KRW 15.7 billion exchangeable into HLB shares held by the company.

The company said it would use the proceeds to strengthen its operating profit base and work to resolve its investment-caution designation. In February 2026, a filing disclosed a disposal of HLB shares by the largest shareholder aimed at improving the financial structure.

An August 2026 press report described a structure in which HLB Cell is transferred to HLB Innovation, supplying KRW 36.2 billion in cash to HLB Life Science, with the burden shifting to HLB Innovation.

Short-term borrowings reportedly rose from KRW 20.3 billion at the end of 2025 to KRW 40.6 billion at the end of the first half of 2026. The company has also said it will pursue new businesses and global expansion to raise shareholder value.

The next items to track are where quarterly revenue settles after the OEM exit and whether operating losses turn into a profit base, which will be visible in the full-year results for the year ending December 2026.

07

Valuation

PER
—
PBR
1.2×
ROE
-8.6%
EPS
-₩187
BPS
₩2,110
Dividend per share
₩0

The share price sits slightly above the book value attributable to controlling shareholders, so the premium over net asset value is modest. Because the company has recorded net losses attributable to controlling shareholders over the last four quarters, a price-to-earnings ratio cannot be calculated.

With earnings-based multiples unavailable, valuation is more usefully read alongside net asset value and the trend in operating results. The cash dividend yield is below the average of the KOSDAQ pharmaceutical sector. Market capitalization is slightly above total equity of KRW 297.7 billion at the end of 2025.

Most of that equity belongs to controlling shareholders at KRW 297.4 billion, so both net asset-based valuation and capital erosion should be considered together.

The 2024 profit and the 2025 loss were driven more by non-operating items than by operating results, so when reading price multiples against earnings, the gap between operating and net income matters. Compared with its past trading band, the current multiple reflects a period in which earnings have not yet recovered.

Total liabilities were KRW 180.4 billion at the end of 2025, more than half of total equity, so the rise in short-term borrowings also bears on financial burden.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Narrowing operating losses and restructuring

The 2025 operating loss narrowed to KRW 22 billion from KRW 24.8 billion in 2024, and the third-quarter 2026 operating loss of KRW 3.49 billion was smaller than a year earlier. The company plans to remove low-profit businesses by exiting the OEM division to change its earnings structure. If the restructuring proceeds as planned, a continued narrowing of operating losses is possible.

Growing medical device exports

According to the company's IR material, the standalone export ratio rose from 4.6% in 2024 to 16.0% in 2025. The CEO said export growth in the medical device division is already showing results. Rising overseas sales as domestic diagnostics demand slows could broaden the revenue base.

Funding and efforts to improve the balance sheet

The company said the KRW 15.7 billion exchangeable bond issued in January 2026 secured operating funds without financing costs. A February 2026 disclosure of an HLB share disposal was also aimed at improving the financial structure.

Total equity of KRW 297.7 billion at the end of 2025 remains above total liabilities of KRW 180.4 billion, which provides a capital base.

09

Bear factors

Shrinking revenue base

Revenue in 2025 was KRW 45.8 billion, down 55.3% year over year. The OEM division accounted for 24.4% of consolidated revenue in 2025, and the company said revenue volatility is unavoidable after its suspension from June 30, 2026.

Quarterly revenue has hovered around KRW 15 billion in 2026, so how much of the suspension effect shows up in quarterly results is a weakness to watch.

Persistent losses and a wider loss ratio

The operating margin worsened to -48.1% in 2025 from -24.3% in 2024. The company has recorded losses for four consecutive years from 2022 to 2025 and for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026.

The combined net loss attributable to controlling shareholders over the last four quarters was KRW 22.8 billion, and it is not yet clear whether the 2024 profit and the fourth-quarter 2025 profit reflect sustainable earnings.

Cash flow and borrowing burden

Operating cash flow was negative in all four years from 2022 to 2025, at KRW -22.9 billion in 2025. Short-term borrowings doubled from KRW 20.3 billion at the end of 2025 to KRW 40.6 billion at the end of the first half of 2026.

Press reports say the intra-group funding structure shifts the burden to HLB Innovation, so the group's overall financial burden also needs to be considered.

10

Risk factors

Investment-caution designation

The company has said it aims to resolve the investment-caution designation by reaching a profit. If the designation remains, trading and funding conditions may stay constrained. The company has not given a timeline for resolution, so confirmation of earnings improvement and any exchange announcement should be tracked.

Intra-group transactions and related-party structure

The January 2026 exchangeable bond was linked to shares of the parent HLB, and a February 2026 disclosure covered a disposal of HLB shares by the largest shareholder. Press reports say the HLB Cell transfer structure moves the funding burden to HLB Innovation. If terms of intra-group transactions change, the company's financial position could also be affected.

Execution risk of the restructuring

Ending the OEM division directly affects revenue and workforce operations. Company Monitor data show 173 employees as of March 2026, so staff and equipment will need to be reallocated after the exit. If export growth in medical devices does not proceed as planned, the effect of the restructuring could be limited.

11

What to watch next

  1. End of December 2026

    This is the closing date for fiscal 2026. It is the starting point for checking how the OEM suspension is reflected in annual revenue and operating loss.

  2. Mid-February 2027

    This is the expected timing of the preliminary 2026 full-year results. Last year's preliminary results were announced on February 20, 2026, and this is the point to check whether the operating loss narrowed and what non-operating items drove fourth-quarter net results.

  3. Late March 2027

    This is the expected timing for filing the 2026 annual business report and holding the regular shareholders' meeting. The 2026 meeting was held on March 31. The annual report will confirm full-year results and show whether conditions for resolving the investment-caution designation have been met.

  4. Mid-May 2027

    This falls within the deadline for filing the first-quarter 2027 report. It is the point to check whether operating losses are moving toward a profit base and whether the net loss attributable to controlling shareholders improves beyond non-operating factors.

12

Overall view

HLB Life Science recorded revenue of KRW 45.8 billion in 2025, an operating loss of KRW 22 billion and a net loss attributable to controlling shareholders of KRW 99.8 billion.

In the third quarter of 2026 the operating loss narrowed to KRW 3.49 billion, but the net loss attributable to controlling shareholders widened to KRW 26.4 billion, showing that quarterly net results are heavily affected by non-operating items.

The OEM exit and rising export share are presented as steps toward a restructured earnings base. On the other side, losses in four consecutive years from 2022, negative operating cash flow in all four years, and higher short-term borrowings remain financial burdens.

Market capitalization is slightly above total equity, and no PER can be calculated from the last four quarters of net losses.

The points to confirm are where quarterly revenue settles after the OEM exit, whether operating losses turn into a profit base, and how the intra-group funding structure affects the company's finances. These will be verifiable in the annual business report and quarterly reports in sequence.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. ideal-life.co.kr
  2. dart.fss.or.kr
  3. mt.co.kr
  4. comp.wisereport.co.kr
  5. m.irgo.co.kr
  6. comp.fnguide.com
  7. news.bizwatch.co.kr
  8. m.news.nate.com
  9. hitnews.co.kr
  10. kind.krx.co.kr
  11. businesspost.co.kr
  12. digitaltoday.co.kr
  13. m.news.nate.com
  14. goinsider.kr
  15. kind.krx.co.kr
  16. comp.fnguide.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis